Airflow Alarm Mid-Batch, a 14-Day Room-Temperature BUD, and a Non-Registered API Source
An outpatient infusion pharmacy prepares a batch of 12 syringes of ceftriaxone 1 g in 0.9% sodium chloride for home-infusion patients. Compounding is done in a horizontal laminar airflow workbench inside an ISO 7 buffer room; the workbench was last certified eight months ago, and pressure differentials are logged daily. A technician starts at 6:00 a.m. At 7:00 a.m. the workbench's airflow alarm sounds and reads 60 fpm. She silences it, finishes the batch by 8:00 a.m., and refrigerates the syringes. Separately, a 100 mL bag of the same drug prepared yesterday and stored at room temperature is labeled with a beyond-use date of 14 days. A shipment of ceftriaxone API arrives with a certificate of analysis from a facility that is not FDA-registered.
1. How is a beyond-use date assigned for these CSPs, and is the 14-day room-temperature date on the bag defensible?
Read the worked answer
A BUD is the output of a documented risk assessment, not a label convention. Under the current USP <797> (the 2023 revision), each CSP is assigned to a category based on its starting components, the compounding process, and the duration of exposure outside ISO 5 conditions. The category fixes the maximum BUD at room temperature, refrigerated, and frozen. The table in the chapter controls; look it up rather than trusting a label that was typed by whoever set up the batch.
On the 100 mL bag: a single-patient bag prepared from a commercial sterile product under routine conditions is a relatively low-complexity CSP, not the highest category. A 14-day room-temperature BUD exceeds the room-temperature limit for the lower categories and can only be defended if the pharmacy can document the highest-category conditions (component sourcing, process validation, environmental monitoring). The bag should be relabeled with a supportable BUD or discarded.
Two principles to state out loud for the inspector:
- A BUD may always be shortened; it may never be extended.
- A BUD cannot cover a period during which the pharmacy was not in control of the CSP's conditions.
Record the category assignment and its basis. That record is what makes the BUD defensible.
2. The airflow alarm sounded during compounding. What happens to the batch, and what must be documented?
Read the worked answer
The alarm is a sterility-failure signal, not a nuisance. Once the ISO 5 workbench is out of specification, the syringes produced after that moment were not prepared under the conditions that justify the assigned BUD - and because you cannot know when the airflow began to drift, the conservative and correct assumption is that the whole batch is compromised.
Actions:
- Quarantine the entire batch; do not release it to patients.
- Stop compounding, tag the workbench out of service, and do not resume until it is certified back into specification. Silencing an alarm and continuing is itself a reportable deviation.
- Open a deviation report: what happened, when, which CSPs were affected, root cause, corrective action, and reviewer sign-off. This is the quality-assurance record the Board and any accreditor will ask for.
- If any suspect syringes already left the building, notify the prescriber and patient, assess for infection, and document. Do not wait for the patient to call.
- Re-prepare today's needed doses and document the reason for the delay and any therapy interruption.
3. May the pharmacy use the ceftriaxone API that arrived with a certificate of analysis from a non-FDA-registered facility?
Read the worked answer
No. Under FDCA section 503A (21 U.S.C. 353a), a pharmacy may compound with a bulk drug substance only if it complies with an applicable USP/NF monograph, is permitted for 503A use (for example, on FDA's 503A bulks list), and is manufactured by an FDA-registered establishment with a valid certificate of analysis.
A COA from a non-registered facility does not satisfy the source requirement, and the pharmacy cannot cure the defect by testing the API in-house. The remedy is not analytical - it is supplier qualification.
What to do:
- Quarantine the shipment; do not use it. Notify the supplier in writing and document the return or destruction.
- Verify registration status for every API supplier and keep the verification in the supplier qualification file.
- If any batch was already prepared with this API, treat it as an investigation: identify affected CSPs, assess whether they can be released, and notify prescribers and patients if they cannot.
- Retain the receiving records; traceability documentation is part of the same file the inspector will request.